Denosumab

Denosumab is a monoclonal antibody treatment for osteoporosis and works by inhibiting osteoclast formation and function.  Denosumab inhibits osteoclasts by binding RANKL (nuclear factor kappa-B ligand), which is an activator of RANK. RANK is a receptor on osteoclasts and osteoclast precursors that, when activated, promotes osteoclast formation, function, and survival.  By inhibiting RANKL, osteoclast activity is reduced, which improves bone density. In addition to osteoclast inhibitor activity that results in risk of osteonecrosis of the jaw and hypocalcemia, monoclonal antibodies also increase the risk of infection.

Class Drugs

• Denosumab

Class Mechanism of Action

Monoclonal antibody that binds RANKL (nuclear factor kappa-B ligand), which decreases osteoclast activity. 

• RANKL ligand activates RANK, which promotes osteoclast formation, function, and survival

Class Applications

Osteoporosis

Class Adverse Effects

Increased risk of infections

Bone and joint pain

Osteonecrosis of the jaw

Hypocalcemia

Drug Table

Drug Name	Application	Comments	Image
Denosumab			"Den" "Sumo Wrestler"